

MARSHALL, GERSTEIN & BORUN LLP  
ATTORNEYS AT LAW  
6300 SEARS TOWER  
233 SOUTH WACKER DRIVE  
CHICAGO, ILLINOIS 60606-6357  
(312) 474-6300  
FAX: (312) 474-0448

RECEIVED  
CENTRAL FAX CENTER

APR 22 2005

04/22/2005

FACSIMILE TRANSMISSION SHEET

TO: Brandon J. Fetterolf, Ph.D.

U.S. Patent & Trademark Office

703 872 9306

FROM:

RE:

PAGES (INCLUDING THIS PAGE): 3

\*\*\*\*\*

*If you do not receive all pages of this fax in good condition, please contact Janet Leathem at (312) 474-6300.*

\*\*\*\*\*


*This transmission contains confidential information intended only for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately.*

PATENT--NO FEE

RECEIVED  
CENTRAL FAX CENTER

APR 22 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	)	Certificate of Transmission
	)	
ANIL GULATI	)	I hereby certify that this
	)	correspondence is being
Serial No.: 10/691,915	)	facsimile transmitted to the
	)	Patent and Trademark Office
Filed: October 23, 2003	)	to Examiner Brandon J.
	)	Fetterolf, at (703)872-9306
For: METHOD AND COMPOSITION FOR	)	on April 22, 2005
PREVENTING AND TREATING SOLID	)	
TUMORS	)	
	)	
Attorney Docket No. 27611/38802A	)	
	)	
Group Art Unit: 1642	)	
	)	James J. Napoli
Examiner: Brandon J. Fetterolf,	)	Registration No. 32,361
Ph.D.	)	Attorney for Applicants

SUPPLEMENTAL RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

This is a supplement to applicant's Response to Restriction Requirement mailed on April 7, 2005. In response to the Office Action dated March 8, 2005, applicant elected the invention represented by the claims of examiner's Group I, namely, claims 1-13, with traverse, for examination. Applicant also elected, erroneously, AN endothelin agonist identified as BQ123. BQ123 is not an endothelin agonist, but rather is an endothelin agonist.

To correct this inadvertent error, applicant hereby requests a substitution of IRL1620 for BQ123 as

the elected species, with traverse. IRL1620 is an endothelin agonist encompassed by applicant's elected claims.


Applicant's undersigned attorney apologizes for this error and any confusion it may have caused.

Should the examiner wish to discuss the foregoing, or any matter of form in an effort to advance this application toward allowance, the examiner is urged to telephone the undersigned at the indicated number.

Respectfully submitted,

**MARSHALL, GERSTEIN & BORUN LLP**

By



James J. Napoli  
(Registration No. 32,361)  
Attorneys for Applicants  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606  
(312) 474-6300

Chicago, Illinois  
April 22, 2005